Antiretroviral Drug Resistance among Drug-Naive HIV-1-Infected Individuals in Djibouti (Horn of Africa)
- 1 October 2005
- journal article
- Published by SAGE Publications in Antiviral Therapy
- Vol. 10 (7) , 855-859
- https://doi.org/10.1177/135965350501000709
Abstract
Objective: To survey the frequency of genotypic anti-retroviral resistance in drug-naive HIV-1-infected Djiboutians. Methods: A national study was conducted in the general population of Djibouti in March 2002 to determine HIV-1 seroprevalence. Blood samples were collected anonymously and plasma samples scoring positive for HIV-1 antibodies were tested for viral load. Genotypic studies were performed with viral RNA from plasma using the consensus technique of the Agence Nationale de Recherche sur le SIDA ( www.hivfrenchresistance.org ). Mutations were identified using the International AIDS Society-USA resistance panel and resistant virus was defined according to the ANRS algorithm. Results: A panel of 2423 individuals representing the general population of Djibouti was included. Antibodies were detected in 53 of 2423 samples tested. The HIV-1 seroprevalence in the general population was 2.2%. Genotype C was the most prevalent, and the other isolates were CRF_02 AG, or subtype A or D. Forty-seven of the 53 samples were tested for genotypic resistance, and mutations concerning all three classes of antiretrovirals were found. The most frequent were secondary mutations associated with protease inhibitors (PIs): M36I, R41K and K20I/R. A few strains displayed primary mutations (the non-nucleoside reverse transcriptase inhibitor [NNRTI]-associated mutations K101E, K103T, L100I and G190V; the PI-associated mutation N88D; and the NRTI-associated mutation K65R). The presence of these mutations may be due to the transmission of strains from treated patients. Conclusion: Substantial polymorphism and a few primary mutations are found in HIV-1 non-B subtype isolates from Djiboutian antiretroviral-drug-naive individuals. This needs to be taken into account to adapt antiretroviral regimens and prophylactic schedules locally.Keywords
This publication has 9 references indexed in Scilit:
- Impact of HIV-1 Subtype and Antiretroviral Therapy on Protease and Reverse Transcriptase Genotype: Results of a Global CollaborationPLoS Medicine, 2005
- Intrapartum Exposure to Nevirapine and Subsequent Maternal Responses to Nevirapine-Based Antiretroviral TherapyNew England Journal of Medicine, 2004
- HIV Drug ResistanceNew England Journal of Medicine, 2004
- Parameters Driving the Selection of Nelfinavir-Resistant Human Immunodeficiency Virus Type 1 VariantsJournal of Virology, 2003
- Prevalence of Drug-Resistance-Associated Mutations in Antiretroviral Drug-Naive Zambians Infected with Subtype C HIV-1AIDS Research and Human Retroviruses, 2003
- The prevalence and determinants of the K65R mutation in HIV-1 reverse transcriptase in tenofovir-naive patientsAIDS, 2002
- Time Trends in Primary HIV-1 Drug Resistance Among Recently Infected PersonsJAMA, 2002
- Genetic Analysis of HIV Type 1 Strains in Bujumbura (Burundi): Predominance of Subtype C VariantAIDS Research and Human Retroviruses, 2001
- Reduced Susceptibility of Human Immunodeficiency Virus Type 1 (HIV-1) from Patients with Primary HIV Infection to Nonnucleoside Reverse Transcriptase Inhibitors Is Associated with Variation at Novel Amino Acid SitesJournal of Virology, 2000